Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a dose-ranging study of AIC-001 for pre-emptive treatment of HCMV viremia
2006-006148-69Phase 2Completed
- Sponsor
- AiCuris
- Start
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of letermovir in cytomegalovirus disease (CMV) (2 arms), sponsored by AiCuris. Primary endpoints: Primary safety and tolerability of AIC-001 over 14 days and Primary antiviral activity of AIC-001. Started Dec 2006; status: completed.
02
Drugs
letermovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2006-006148-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006148-69.